INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 263 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $246,000 | -36.9% | 4,406 | -18.0% | 0.00% | 0.0% |
Q1 2022 | $390,000 | -39.2% | 5,375 | -0.9% | 0.00% | -33.3% |
Q4 2021 | $641,000 | -19.6% | 5,426 | -8.7% | 0.00% | -25.0% |
Q3 2021 | $797,000 | -22.9% | 5,944 | -7.1% | 0.00% | -20.0% |
Q2 2021 | $1,034,000 | +50.3% | 6,396 | -25.5% | 0.01% | +25.0% |
Q1 2021 | $688,000 | +43.0% | 8,585 | -3.2% | 0.00% | +33.3% |
Q4 2020 | $481,000 | +174.9% | 8,868 | 0.0% | 0.00% | +200.0% |
Q3 2020 | $175,000 | -29.7% | 8,868 | -25.8% | 0.00% | -50.0% |
Q2 2020 | $249,000 | +128.4% | 11,946 | +58.3% | 0.00% | – |
Q1 2020 | $109,000 | 0.0% | 7,547 | 0.0% | 0.00% | – |
Q4 2019 | $109,000 | +153.5% | 7,547 | +125.5% | 0.00% | – |
Q3 2019 | $43,000 | -4.4% | 3,347 | +21.7% | 0.00% | – |
Q2 2019 | $45,000 | -2.2% | 2,750 | 0.0% | 0.00% | – |
Q1 2019 | $46,000 | +24.3% | 2,750 | 0.0% | 0.00% | – |
Q4 2018 | $37,000 | -56.5% | 2,750 | -11.3% | 0.00% | – |
Q2 2018 | $85,000 | – | 3,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |